•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Moderna's stock is rising on hopes it could develop a hantavirus vaccine. Shares of Moderna (MRNA) were up nearly 7% in recent trading, following a Bloomberg report that the company confirmed it's working on a hantavirus vaccine. The virus has made headlines in recent weeks after cruise ship passengers on the MV Hondius tested positive for it. Moderna did not respond to Investopedia's request for comment in time for publication. Why This Matters to Investors Moderna's recent stock gains have helped pare back some of its losses in recent years amid worries about its dependence on COVID-19 vaccine revenues. The World Health Organization said eight cases of the virus have been identified so far tied to the MV Hondius cruise ship that docked in the Canary Islands over the weekend, including three deaths. Yesterday, government planes reportedly started carrying passengers back to their home countries to be quarantined. Officials have said that the risk to the broader public remains low. With Monday's gains, Moderna shares have nearly doubled since the start of the year, though they remain nearly 90% off their 2021 highs.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
